Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharmascience Appeals Canadian Copaxone 40mg Ruling

Mixed Verdict Involving Teva Sees One Patent Invalidated And Another Upheld

Executive Summary

A mixed verdict in Canadian litigation involving Pharmascience has seen one patent protecting Teva’s Copaxone 40mg upheld and one deemed invalid. Pharmascience plans to appeal.

You may also be interested in...



US Copaxone patents confirmed as invalid

Four patents protecting Teva’s Copaxone (glatiramer acetate) 40mg/ ml thrice-weekly formulation are invalid as obvious, the US Court of Appeals has confirmed in two parallel decisions. The decisions remove the threat of damages against Mylan and Sandoz, which launched glatiramer acetate (GA) 40mg pre-filled syringes ‘at risk’ pending Teva’s appeal (Generics bulletin, 16 February 2018, page 15).

What Aspects Will Give Humira Biosimilars The Edge In 2023?

With multiple Humira biosimilars slated for launch in the US next year, some simultaneously, a Vizient survey provides some insights into what could be the most important differentiating aspects. Generics Bulletin speaks to Steven Lucio, Vizient senior principal of pharmacy solutions, about the findings.

Olon Expands On Multiple Fronts

Italian API and CDMO specialist Olon is expanding its high-potency capabilities at a site in India, at the same time as unveiling plans to invest a further €30m in a domestic biotech hub.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel